Vivos Inc

Vivos Inc. expands manufacturing globally to boost growth, despite volatile stock and negative earnings; investors watch as expansion could reverse its financial trajectory.

Vivos Inc. faces sharp volatility and negative P/E/B ratios, leaving investors wary despite therapeutic progress—understand the risks before buying.

Vivos Inc.

Vivos Inc’s animal therapy progress faces a harsh backdrop: negative P/E and P/B ratios, low stock price, and investor skepticism. Is innovation enough to lift its health‑care valuation?

Vivos Inc. (OTC) faces volatility and a negative P/E, but seeks strategic growth and operational efficiency to boost its market position.

Vivos Inc. on the OTC Bulletin Board: volatile stock, a $35M market cap, negative P/E, and the strategic path to profitability and investor trust.

Vivos Inc., a publicly traded company on the OTC Bulletin Board, is facing financial challenges, including a negative price-to-earnings ratio and significant price fluctuations, which may deter investors but also present opportunities for those will…

Vivos Inc. has achieved a significant milestone by certifying the University of Florida Veterinary Hospital for its IsoPet therapy, but its stock price has experienced notable fluctuations in the past year.

Vivos Inc. has reported record growth in its IsoPet animal cancer treatments during Q1 2025, despite market volatility, positioning the company as a key player in the animal health care industry.